Pharmaceutical Executive-09-01-2018

Pharmaceutical Executive
Features

September 21, 2018

Pharm Exec talks with CSL Limited’s top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Pharmaceutical Executive
Features

September 20, 2018

While definitions for “specialty drug” vary-and distribution and pricing/reimbursement factors remain complicated-this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.

Pharmaceutical Executive
Features

September 19, 2018

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

Pharmaceutical Executive

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.

Pharmaceutical Executive

How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients nonsense mutations.

Pharmaceutical Executive
Features

September 13, 2018

How low-cost drugs can succeed in the specialty pharmacy channel.

Pharmaceutical Executive
Features

September 12, 2018

Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance-return on invested capital.

Pharmaceutical Executive
From the Editor

September 11, 2018

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Pharmaceutical Executive
Columns

September 01, 2018

New Action Plan aims to streamline development, but rebates and reimbursement block market access.

Columns
Pharmaceutical Executive

September 01, 2018

How industry can benefit from this new view on innovation.

Special Sponsored Section
Pharmaceutical Executive

September 01, 2018

Faced with looming uncertainties triggered by the upcoming Brexit, the United Kingdom’s life sciences sector, which constitutes one of the last big remaining bastions of British industry, is not about to rest on its laurels.

Issue PDF
Pharmaceutical Executive

September 01, 2018

Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.